A fast-paced week filled with opportunities!

Thanks to everyone we met – we really appreciated the quality of our discussions, and are as excited as ever to be working alongside you on your #stroke #preclinical projects.

Thanks also to CCI France and Business France, for supporting the export of innovative French CROs and biotechs.

We hope that you are not being too hard hit by the current crisis, and that you and your family and friends remain healthy.

Like many others, we have reorganized our production schedule to ensure continuity of service while keeping our team safe. Although things may take a little longer, our team is standing by to conduct your studies to the high-quality standards that underpin our reputation.

This period of uncertainty also offers an opportunity for us to reflect on our R&D strategy and be proactive with regards to client projects.

We find ourselves with more time to think ahead – and so do you.

As always, our experts are here to offer support with your preclinical expertise challenges.

Please do feel free to get in touch and contact us here.

Wishing you all the best in these difficult times! 

Created in 2017, the STROK@LLIANCE brand has quickly built a reputation for quality and success in the field of preclinical services in neurology.

It is a real pleasure for us to see our brand building value.

Having already secured trademark protection in Europe, ETAP-Lab is proud to announce that the Japanese patent office has now approved our application to register the STROK@LLIANCE trademark.

We decided to include an image of the official document because, in addition to its legal value, it is beautifully decorated with motifs featuring peacocks and bamboo!

Contact us

For several years now, Prof. Denis Vivien’s team (Laboratoire PhIND, U1237, Caen), our STROK@LLIANCE partner, has been looking into in the potential of N-Acetylcysteine (NAC, Mucomyst®) for thrombolysis of resistant clots during the acute phase of ischemic stroke.

While this old molecule is well known as a bronchial fluidizer, it is not generally thought of as having anything to do with strokes. However, Prof. Vivien and his team have found that similarities exist between blood clots and nasal secretions. As the l’Express article reports, Prof. Vivien states that they “are all made up of large close-structural proteins that form a mesh, with white and red blood cells trapped on one side and nasal secretions on the other”. More specifically, the Van Willebrand factor that enables platelet aggregation has structural similarities with the mucins present in mucus.

Preclinical trials have shown that NAC has the ability to dissolve platelet clots in human blood samples in vitro, as well as reduce the cerebral injury induced by ischemic stroke in mouse models that are resistant to current thrombolytic therapy.  In this way, “even clots resistant to the best available treatments have been dissolved”.

In spring 2020, Prof. Vivien and his team will begin a clinical trial with 200 patients across 10 hospitals. This project holds out hope for better stroke management during the acute phase that is the leading cause of severe acquired disability, worldwide. In addition to the ready availability of this molecule, the likelihood of successful development is enhanced by the fact that we are already familiar with its side effects and how to control them.

All the know-how and methodologies implemented for the preclinical characterization of NAC have been transferred to STROK@LLIANCE, which is the only CRO 100% dedicated to preclinical stroke. Find out more about all our models and services on our website.

Contact us

STROK@LLIANCE will participate to MEDICA next 19 November in Dusseldorf. Our expert Dr. Nicolas Violle (CEO) will present Strok@lliance’s services in the field of stroke preclinical research. Our partner CYCERON, represented by Dr. Benoit Haelewyn, will also be present during this event.

By taking advantage of the CYCERON facilities, STROK@LLIANCE accesses such cutting-edge technologies as 7T-MRI and PET-scan.

Please feel free to contact us if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

Contact us

Ischemia-reperfusion injury:
Recent clinical data challenge the translational value of mechanical MCAO models of stroke in rodents

Ischemia-reperfusion injury has been hypothesized to play a major role in the physiopathology of acute stroke since it has been demonstrated that abrupt reperfusion induces secondary brain damages responsible for up to 70% of the final ischemic lesion size in rodents.

However, such a critical role for abrupt reperfusion on the ischemic injury has never been clearly demonstrated in human. Indeed, clinical data were still lacking up to recently. It is of importance considering that mechanical ischemia-reperfusion with a monofilament has been considered as a gold-standard model of stroke for decades.

That’s why Strok@lliance‘s academic partner (PhIND laboratory, Caen) reanalysed data from Aspiration vs Stent Retriever for Successful Revascularization (ASTER) clinical study to evaluate cerebral infarct progression after abrupt reperfusion in thrombectomised patients.

The results, recently published in the journal Stroke, did not evidence any lesion growth 24h after complete reperfusion in most patients.

This discrepancy between clinical and preclinical pathophysiologies question the translational value of the mechanical ischemia-reperfusion model in rodents and should be considered during preclinical evaluation of neuroprotective strategies. In particular, it indicates that this model is not a translational model of thrombectomy nor a suitable model to test neuroprotective agent efficacy during the acute phase of stroke.

It underlines the urgent need for more translational models. That’s why we, at Strok@lliance, are committed to provide innovative ischemic stroke models to support the development of new drugs.

Link toward the article

2018 has been a rewarding year for Strok@lliance as a result of several projects completed and new models that have been developed! Here is a brief summary of the key points regarding our development and achievements:

  • Strok@lliance is proud to count new clients from mid-size to top 10 pharma companies.
  • Several new tailor-made models have been added to our catalogue according to customers request including:

→ A double autologous blood injection in cisterna magna, a complex model of subarachnoidian hemorrhage in rat.

→ Models of ischemia-reperfusion in juvenile rats (28 days) enabling Strok@lliance to predict the effects related to drug administration on children.

  • Strok@lliance obtained a grant from French research ministry to start a CIFRE Thesis. The Thesis will start in spring 2019 and will focused on the refinement of our thrombin-induced stroke models by the addition of comorbidities (aging, hypertension, diabetes…).
  • Strok@lliance team is growing with the recruitment of new technicians, empowering us to carry out more and more projects with the same level of quality and efficiency.

After these past two years, Strok@lliance is pursuing its objective of becoming a reference as the preclinical CRO dedicated to stroke with an increasingly number of projects planned for 2019.

Our team is grateful for the trust customers placed in us to design and validate stroke models, as well as to carry out their pre-clinical studies. We are committed to provide services of quality and are constantly evolving to answer customer specific demands.